PER-010-11未知未知

ENDOCRINE THERAPY WITH OR WITHOUT ANTI-VEGF THERAPY: A RAMDOMIZED, PHASE III TRAIL OF ENDOCRINE THERAPY ALONE OR ENDOCRINE THERAPY PLUS BEVACIZUMAB (NSC 704865; IND 7921) FOR WOMEN WITH HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER

GRUPO DE ESTUDIOS CLINICOS ONCOLOGICO DEL PERU GECOPERU, CANCER AND LEUKEMIA GROUP B (CALGB),0 个研究点目标入组 0 人开始时间: 2011年7月7日最近更新: 2023年9月4日

试验速览

暂无简介。

•ALL QUESTIONS TO CONSIDER THE SELECTION CRITERIA SHOULD BE DIRECTED TO STUDY CALGB ADDRESS: PLEASE NOTE THAT THE STUDY ADDRESS CAN NOT GRANT THE WAIVER ELIGIBILITY REQUIREMENTS.
•4.1 DOCUMENTATION HISTOLOGIC: HISTOLOGIC CONFIRMATION INVASIVE BREAST CANCER FEMALE IN THE STADIUM PRIMARY OR METASTATIC.
•4.1.1 STADIUM: DISEASE IN STAGE IV OR IIIB (USING THE CRITERIA AJCC 6TH EDITION) NO LOCAL THERAPY SENSITIVE.
•4.2 PATIENT MAY NOT HAVE A MALIGNANT TUMOR CURRENT ASSETS THAN NON MELANOMA SKIN CANCER. PATIENTS ARE NOT CONSIDERED TO HAVE A MALIGNANT TUMOR CURRENT ASSETS IF THEY HAVE COMPLETED TERAPLA AND ARE CONSIDERED BY YOUR DOCTOR WITH LESS THAN 30% OF RISK OF RECURRENCE.
•4.3 HORMONE RECEPTOR STATUS:
•TUMORS (SITES BOTH PRIMARY AND METASTATIC) MUST STATE THE ESTROGEN RECEPTOR (ER) AND / OR PROGESTERONE (PgR) ≥ 1% POSITIVE CELL BE CONSIDERED.
•4.4 AGE ≥ 18 YEARS.
•4.5 STATUS MENOPAUSAL
•4.5.1 POSTMENOPAUSAL WOMEN ARE ELIGIBLE FOR THIS TEST. PRIOR TO REGISTRATION STATUS TO STUDY TO BE DEFINED MENOPAUSAL TO THE CRITERIA DESCRIBED BELOW.
•POSTMENOPAUSAL 4.5.2 ARE DEFINED AS:
•≥ 55 YEARS OLD AND A YEAR OR MORE OF AMENORRHEA
•AGE <55 YEARS AND ONE YEAR OR MORE OF AMENORRHEA, ESTRADIOL WITH A TEST <20 pg / ml.

发起方

GRUPO DE ESTUDIOS CLINICOS ONCOLOGICO DEL PERU GECOPERU, CANCER AND LEUKEMIA GROUP B (CALGB),